CEBPA and acute myeloid leukemia: In addition, compared with KMT2CWT AML, KMT2CMUT AML had significantly higher frequencies of CEBPA (50.0% vs. 20.6%, p = .004), GATA2 (25.0% vs. 6.1%, p = .007) and BCOR (20.0% vs. 4.9%, p = .016) mutations (Figure 1C).